Lamb Weston, Adecoagro, and More Stocks See Action From Activist Investors -- Barrons.com

Dow Jones10-26

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Oct. 17 through Oct. 23, 2024. Source: VerityData

Activist Holdings

Lamb Weston Holdings Jana Partners disclosed a new position in the potato-products maker of 7,288,845 shares. Jana reported that it purchased 826,654 Lamb Weston shares from Aug. 22 through Oct. 17 at prices ranging from $60.88 to $71.36 each. Included in Jana's stake are 32,304 call options for 3,230,400 shares with a strike price of $30; those options expire on Dec. 20. Jana also revealed a slate of four director nominees to stand for election at Lamb Weston's annual meeting. Following the purchases, Jana now owns a 5.1% stake in Lamb Weston.

Increases in Holdings

Adecoagro Tether Holdings raised its stake in the agricultural company to 16,799,590 shares. Tether purchased 1,751,341 Adecoagro shares from Oct. 14 through Oct. 18 at prices ranging from $11 to $11.38 each. Tether revealed an initial stake of 10,048,249 Adecoagro shares that it purchased from July 29 through Aug. 16 at prices ranging from $9.45 to $11.66 each; Tether purchased an additional five million shares from Sept. 3 through Sept. 26 at prices ranging from $11.02 to $11.91 each. Following the purchases, Tether now owns a 16.4% stake in Adecoagro, which owns farmland and industrial facilities in Argentina, Brazil, and Uruguay.

Decreases in Holdings

Soleno Therapeutics Carlyle Group cut its stake in the biopharmaceutical company to 2,003,101 shares. Carlyle Group reported that it sold 499,047 Soleno Therapeutics shares from Oct. 14 through Oct. 17 at prices ranging from $53 to $55.24 apiece. Following the latest sales, Carlyle Group now owns 4.99% of Soleno Therapeutics' outstanding stock, below the 5% threshold that would require Carlyle Group to disclose further sales of Soleno Therapeutics stock. Shares have gained more than 30% during the year.

nCino Insight Venture Partners X lowered its stake in the provider of a software-as-a-service, or SaaS, for banks to 12,513,467 shares. Insight Venture Partners did so through the sale of 3,500,000 nCino shares from Oct. 16 through Oct. 18 at prices ranging from $36 to $36.65 each through a Rule 10b5-1 plan adopted on April 10. Following the latest sales, Insight Venture Partners continues to own 10.8% of nCino's outstanding stock. Shares of nCino have gained about 14% during the year.

Bel Fuse Gamco Investors decreased its stake in the maker of electronic components to 242,138 Class A shares. Gamco Investors did so through the sale of 23,913 Class A Bel Fuse shares from Oct. 7 through Oct. 16 at prices ranging from $100 to $104.77 each. Following the latest sales, Gamco Investors continues to own 11.5% of Bel Fuse's outstanding Class A stock. The shares have gained nearly 60% year to date.

Email: editors@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

October 25, 2024 14:44 ET (18:44 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment